文献速递新发突发、热带与寄生虫病

恶性疟原虫传播阻断疫苗Pfs230D1-EPA和Pfs25-EPA在氢氧化铝佐剂中用于健康马里成人的1期随机对照试验

Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial.
PubMed 文献 · Lancet Infect Dis · 2023-07-24

该研究在马里疟疾高流行区成人中开展1期随机对照试验,比较Pfs230D1-EPA与Pfs25-EPA疫苗的安全性和免疫原性;Pfs230D1诱导产生持久的功能活性,而Pfs25未诱导;直接皮肤饲蚊试验可检测寄生虫传播,但需增加事件率以评估疫苗效果。

要点

  • Pfs230D1疫苗在马里成人中诱导产生持久的血清功能活性,而Pfs25疫苗未诱导。
  • Pfs230D1和联合组的传播减少活性在第三剂后出现,第四剂后分别达88.9%和85.0%。
  • 直接皮肤饲蚊试验中疫苗组阳性检测比例与对照组无显著差异。

核心结论

  • Pfs230D1疫苗而非Pfs25疫苗在马里成人中诱导产生持久的血清功能活性。
  • 直接皮肤饲蚊试验可检测寄生虫向蚊媒的传播,但需增加事件率以评估疫苗效果。

研究设计与样本

  • 在马里疟疾高流行区Bancoumana开展先导安全性研究,随后进行双盲、区组随机、对照主期试验。
  • 18-50岁健康、非妊娠、非哺乳期、知情同意的成人居民按1:1:1:1随机分配接受四剂疫苗,分别于第0、1、4.5和16.5个月接种。
  • 主队列200名参与者接受四剂系列:47 μg Pfs25-EPA/氢氧化铝加生理盐水(n=50,25%)、40 μg Pfs230D1-EPA/氢氧化铝加生理盐水(n=49,25%)、47 μg Pfs25-EPA/氢氧化铝加40 μg Pfs230D1-EPA/氢氧化铝(n=50,25%)或对照疫苗(Twinrix或Menactra)加生理盐水(n=51,25%)。
  • 先导安全性队列25名参与者随机分配至每组5人(20%),接受两剂系列:Pfs25-EPA/氢氧化铝(16 μg)、Pfs230D1-EPA/氢氧化铝(15 μg)或对照,随后接受Pfs25-EPA/氢氧化铝(16 μg)加Pfs230D1-EPA/氢氧化铝(15 μg)或对照加生理盐水。
  • 主要终点为按治疗人群分析的安全性和耐受性,次要终点为按治疗人群分析的免疫原性(ELISA、标准膜饲喂试验和蚊直接皮肤饲喂试验)。

主要发现

  • 先导安全期和主期的疫苗接种均耐受良好。
  • 多数受种者在接种两剂Pfs230D1或三剂Pfs25后转为血清阳性,此后峰值滴度随每剂次增加(Pfs230D1几何均值:77.8 [95% CI 56.9-106.3]、146.4 [108.3-198.0]和410.2 [301.6-558.0];Pfs25几何均值177.7 [130.3-242.4]和315.7 [209.9-474.6])。
  • 功能活性(平均峰值传播减少活性)在Pfs230D1组第三剂后为74.5% [66.6-82.5],第四剂后为88.9% [81.7-96.2];Pfs25加Pfs230D1组第三剂后为68.6% [57.3-79.8],第四剂后为85.0% [78.4-91.5];Pfs25组第三剂后为58.2% [49.1-67.3],第四剂后为58.2% [48.5-67.9],未出现功能活性。
  • Pfs230D1的传播减少活性在第四剂后10周仍持续(73.7% [64.1-83.3])。
  • 传播减少活性达80%的估计值分别为:Pfs25 1659 ELISA单位、Pfs230D1 218 ELISA单位、Pfs230D1加Pfs25 223 ELISA单位。

关键数值与推荐

  • Pfs230D1组第四剂后传播减少活性为88.9% [95% CI 81.7-96.2],Pfs25加Pfs230D1组为85.0% [78.4-91.5]。
  • Pfs25组第三剂后传播减少活性为58.2% [49.1-67.3],第四剂后为58.2% [48.5-67.9]。
  • Pfs230D1传播减少活性在第四剂后10周为73.7% [64.1-83.3]。
  • 传播减少活性80%的估计值:Pfs25 1659 ELISA单位,Pfs230D1 218 ELISA单位,Pfs230D1加Pfs25 223 ELISA单位。
  • 疫苗组阳性检测比例与对照组无显著差异(Pfs25组3% vs 对照组2%;Pfs230D1组2% vs 对照组2%;联合组1% vs 对照组2%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 直接皮肤饲喂试验可检测寄生虫向蚊媒的传播,但需增加事件率以评估疫苗效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malaria transmission-blocking vaccines target mosquito-stage parasites and will support elimination programmes. Gamete vaccine Pfs230D1-EPA/Alhydrogel induced superior activity to zygote vaccine Pfs25-EPA/Alhydrogel in malaria-naive US adults. Here, we compared these vaccines in malaria-experienced Malians. METHODS: We did a pilot safety study then double-blind, block-randomised, comparator-controlled main-phase trial in malaria-intense Bancoumana, Mali. 18-50-year-old healthy non-pregnant, non-breastfeeding consenting adult residents were randomly assigned (1:1:1:1) to receive four doses at months 0, 1, 4·5, and 16·5 of either 47 μg Pfs25, 40 μg Pfs230D1 or comparator (Twinrix or Menactra)-all co-administered with normal saline for blinding-or 47 μg Pfs25 plus 40 μg Pfs230D1 co-administered. We documented safety and tolerability (primary endpoint in the as-treated populations) and immunogenicity (secondary endpoint in the as-treated populations: ELISA, standard-membrane-feeding assay, and mosquito direct skin feed assay). This trial is registered at ClinicalTrials.gov, NCT02334462. FINDINGS: Between March 19, and June 2, 2015, we screened 471 individuals. Of 225 enrolled for the pilot and main cohorts, we randomly assigned 25 participants to pilot safety cohort groups of five (20%) to receive a two-dose series of Pfs25-EPA/Alhydrogel (16 μg), Pfs230D1-EPA/Alhydrogel (15 μg) or comparator, followed by Pfs25-EPA/Alhydrogel (16 μg) plus Pfs230D1-EPA/Alhydrogel (15 μg) or comparator plus saline. For the main cohort, we enrolled 200 participants between May 11 and June 2, 2015, to receive a four-dose series of 47 μg Pfs25-EPA/Alhydrogel plus saline (n=50 [25%]; Pfs25), 40 μg Pfs230D1-EPA/Alhydrogel plus saline (n=49 [25%]; Pfs230D1), 47 μg Pfs25-EPA/Alhydrogel plus 40 μg Pfs230D1-EPA/Alhydrogel (n=50 [25%]; Pfs25 plus Pfs230D1), or comparator (Twinrix or Menactra) plus saline (n=51 [25%]). Vaccinations were well tolerated in the pilot safety and main phases. Most vaccinees became seropositive after two Pfs230D1 or three Pfs25 doses; peak titres increased with each dose thereafter (Pfs230D1 geometric mean: 77·8 [95% CI 56·9-106·3], 146·4 [108·3-198·0], and 410·2 [301·6-558·0]; Pfs25 geometric mean 177·7 [130·3-242·4] and 315·7 [209·9-474·6]). Functional activity (mean peak transmission-reducing activity) appeared for Pfs230D1 (74·5% [66·6-82·5]) and Pfs25 plus Pfs230D1 (68·6% [57·3-79·8]), after the third dose and after the fourth dose (88·9% [81·7-96·2] for Pfs230D1 and 85·0% [78·4-91·5] Pfs25 plus Pfs230D1) but not for Pfs25 (58·2% [49·1-67·3] after the third dose and 58·2% [48·5-67·9] after the fourth dose). Pfs230D1 transmission-reducing activity (73·7% [64·1-83·3]) persisted 10 weeks after the fourth dose. Transmission-reducing activity of 80% was estimated at 1659 ELISA units for Pfs25, 218 for Pfs230D1, and 223 for Pfs230D1 plus Pfs25. After 3850 direct skin feed assays, 35 participants (12 Pfs25, eight Pfs230D1, five Pfs25 plus Pfs230D1, and ten comparator) had transmitted parasites at least once. The proportion of positive assays in vaccine groups (Pfs25 33 [3%] of 982 [-0·013 to 0·014], Pfs230D1 22 [2%] of 954 [-0·005 to 0·027], and combination 11 [1%] of 940 [-0·024 to 0·002]) did not differ from that of the comparator (22 [2%] of 974), nor did Pfs230D1 and combination groups differ (-0·024 to 0·001). INTERPRETATION: Pfs230D1 but not Pfs25 vaccine induces durable serum functional activity in Malian adults. Direct skin feed assays detect parasite transmission to mosquitoes but increased event rates are needed to assess vaccine effectiveness. FUNDING: Intramural Research Program of the National Institute of Allergy and Infectious Diseases and US National Institutes of Health.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sagara I, Healy SA, Assadou MH, et al. Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial. Lancet Infect Dis. 2023. PMID: 37499679. doi:10.1016/S1473-3099(23)00276-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。